Skip to main content

Table 2 Gag mutations with significant frequency changes across VE and VL and their associated epitopes

From: Next-generation sequencing analyses of the emergence and maintenance of mutations in CTL epitopes in HIV controllers with differential viremia control

Patient

Mutation

Frequency (%)

Epitope

VE

VL

HLA

Position

Sequence

Location

EC02

A83S

0.0

22.9

B52

Gag (74–82)

ELRSLYNTV

A

S278C

0.0

22.8

B52

Gag (275–282)

RMYSPTSI

I

EC11

K26R

0.0

94.1

B81

Gag (19–27)

IRLRPGGKK

I

EC42

E40Q

Ea

17.7

B51

Gag (36–44)

WASRELERF

I

N126S

Sa

79.9

B15

Gag (127–135)

QVSQNYPIV

A

N126R

Sa

21.0

B15

Gag (127–135)

QVSQNYPIV

A

EC18

K28Q

33.9

0.0

B07

Gag (22–30)

RPGGKKHYM

I

K28R

65.9

99.6

B07

Gag (22–30)

RPGGKKHYM

I

I34L

21.0

99.8

B52

Gag (34–44)

LVWASRELERF

I

R39K

0.0

99.5

B52

Gag (34–44)

LVWASRELERF

I

R43Q

17.2

0.0

B52

Gag (34–44)

LVWASRELERF

I

R76K

20.2

0.0

B07

Gag (71–79)

GSEELRSLY

I

T280A

79.7

0.0

B07/B52

Gag (274–282)/Gag (275–282)

VRMYSPVSI/RMYSPTSI

I

T280V

19.9

0.0

B07/B52

Gag (274–282)/Gag (275–282)

VRMYSPVSI/RMYSPTSI

I

T280S

0.0

99.7

B07/B52

Gag (274–282)/Gag (275–282)

VRMYSPVSI/RMYSPTSI

I

VC10

N126S

0.7

94.2

B15

Gag (127–135)

QVSQNYPIV

A

N126S

0.0

5.6

B15

Gag (127–135)

QVSQNYPIV

A

A146P

39.9

37.6

B15

Gag (144–152)/Gag (147–155)

HQAISPRTL/ISPRTLNAW

I

A146S

59.3

62.4

B15

Gag (144–152)/Gag (147–155)

HQAISPRTL/ISPRTLNAW

I

S173T

43.1

67.5

B15

Gag (168–175)

VIPMFSAL

I

I223V

41.6

32.4

B15

Gag (226–236)

GQMREPRGSDI

A

T280S

45.3

66.7

B15/B52

Gag (274–282)/Gag (275–282)

VRMYSPTSI/RMYSPTSI

I

T280I

52.7

17.4

B15/B52

Gag (274–282)/Gag (275–282)

VRMYSPTSI/RMYSPTSI

I

VC14

V82I

99.7

77.9

B44

Gag (78–86)

LYNTVATLY

I

C87Y

97.4

99.7

B44

Gag (78–86)

LYNTVATLY

A

I147L

99.7

81.1

B42

Gag (144–152)

HQAISPRTL

I

S310T

99.7

81.1

B44

Gag (306–316)

AEQASQDVKNW

I

VC15

V82I

43.4

84.9

B57

Gag (76–86)

RSLYNTVATLY

I

D121A

30.6

81.8

B57

Gag (114–122)

KTQQAAADK

I

T122A

49.2

82.1

B57

Gag (114–122)

KTQQAAADK

I

H124N

59.7

0.0

B57

Gag (114–122)

KTQQAAADK

A

N271T

0.0

24.7

B57

Gag (274–282)

VRMYSPVSI

A

T280V

1.8

98.8

B57

Gag (274–282)

VRMYSPVSI

I

VC16

I34L

32.2

0.0

B57

Gag (34–44)

LVWASRELERF

I

V35I

32.6

0.0

B57

Gag (34–44)

LVWASRELERF

I

V46I

29.3

0.0

B57

Gag (34–44)

LVWASRELERF

A

V82L

25.9

0.0

B57

Gag (76–86)

RSLYNTVATLY

I

A118P

24.9

0.0

B57

Gag (114–122)

KTQQAAADK

I

A119T

24.9

0.0

B57

Gag (114–122)

KTQQAAADK

I

T122A

4.8

71.6

B57

Gag (114–122)

KTQQAAADK

I

G123K

24.7

0.0

B57

Gag (114–122)

KTQQAAADK

A

H124N

99.1

64.4

B57/B14

Gag (114–122)/Gag (127–135)

KTQQAAADK/QVSQNYPIV

A

H124S

0.7

35.3

B57/B14

Gag (114–122)/Gag (127–135)

KTQQAAADK/QVSQNYPIV

A

S125R

30.9

0.0

B57/B14

Gag (114–122)/Gag (127–135)

KTQQAAADK/QVSQNYPIV

A

Q127H

76.7

98.3

B14

Gag (127–135)

QVSQNYPIV

I

I138L

75.5

94.1

B14

Gag (127–135)

QVSQNYPIV

A

A146P

74.6

99.4

B57

Gag (145–155)

QAISPRTLNAW

I

A163G

78.3

75.4

B14/B57

Gag (160–168)/Gag (162–172)

EEKAFSPEV/KAFSPEVIPMF

I

S165N

77.6

75.0

B14/B57

Gag (160–168)/Gag (162–172)

EEKAFSPEV/KAFSPEVIPMF

I

V168T

0.0

22.8

B14/B57

Gag (160–168)/Gag (162–172)

EEKAFSPEV/KAFSPEVIPMF

I

S173T

37.7

74.1

B57

Gag (162–172)

KAFSPEVIPMF

A

V191I

33.3

99.4

B14

Gag (183–191)

DLNMMLNIV

I

T242N

78.4

99.5

B57

Gag (240–249)

TSTLQEQIGW

I

D295N

0.0

9.9

B14

Gag (298–306)

DRFFKTLRA

A

K335R

49.2

58.9

B14

Gag (329–337)

DCKTILKAL

I

A340G

70.9

96.6

B14

Gag (329–337)

DCKTILKAL

A

  1. aConsensus amino acid from the available bulk sequence shown instead of frequency; Location A—adjacent to epitope; Location I—within epitope